Aromatase inhibitors for breast cancer prevention

Saranya Chumsri, Stephen Yu, Amanda Schech, Gauri Sabnis, Angela Brodie

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

Original languageEnglish (US)
Title of host publicationTrends in Breast Cancer Prevention
PublisherSpringer International Publishing
Number of pages9
ISBN (Electronic)9783319271354
ISBN (Print)9783319271330
StatePublished - Jan 1 2016


  • Aromatase inhibitors
  • Breast cancer
  • Chemoprevention

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Aromatase inhibitors for breast cancer prevention'. Together they form a unique fingerprint.

Cite this